Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4

Journal of the National Cancer Institute

Volumn 90, Issue 16, 1998, Pages 1225-1229

  Rebbeck, Timothy R ^a,b   Jaffe, Julie M ^a   Walker, Amy H ^a   Wein, Alan J ^a   Malkowicz, S Bruce ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER GRADING; CARCINOGENESIS; ENZYME ACTIVITY; GENETIC LINKAGE; GENETIC VARIABILITY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; TESTOSTERONE METABOLISM;

EID: 0032547341     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.16.1225     Document Type: Article

References (19)

1. Giovanncci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer [published erratum appears in Proc Natl Acad Sci U S A 1997;94:8272]. Proc Natl Acad Sci U S A 1997;94:3320-3.
2. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-70.
3. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res 1995;55: 3973-5.
4. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988;263:424-36.
5. Kleinbloesem CH, van Brummelen P, Faber H, Danhof M, Vermeulen NP, Breimer DD. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol 1984;33:3721-4.
6. Murray GI, Taylor VE, McKay JA, Weaver RJ, Ewen SW, Melvin WT, et al. The immunohistochemical localization of drugmetabolizing enzymes in prostate cancer. J Pathol 1995;177:147-52.
7. Richards B, Skoletsky J, Shuber AP, Balfour R, Stern RC, Dorkin HL, et al. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet 1993;2:159-63.
8. Gleason DF. The Veteran's Administration Cooperative Urologic Research Group: histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia: Lea & Febiger; 1977. p 171-98.
9. Beahrs OH, Henson DE, Hutter RV, Kennedy BJ, editors. Manual for staging of cancer. 4th ed. Philadelphia: Lippincott; 1992. p 185-6.
10. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 1993;218: 585-95.
11. Ganguly A, Rock MJ, Prockop DJ. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in doublestranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes [published erratum appears in Proc Natl Acad Sci U S A 1994;91:5217]. Proc Acad Nat Sci U S A 1993;90:10325-9.
12. Waxman DJ, Lapenson DP, Aoyama T, Gelboin HV, Gonzalez FJ, Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys 1991;290:160-6.
13. Coffey DS. Androgen action and the sex accessory tissues. In: Knobil E, Neill JJ, Ewing LL, editors. The physiology of reproduction. New York: Raven Press; 1988. p 1081-118.
14. Vermeulen A. Androgens in male senescence. In: Nieschlag E, Behre HM, editors. Testosterone: action, deficiency, substitution. Berlin: Springer-Verlag; 1980. p 261-76.
15. Vermeulen A, Verdonck L. Some studies on the biological significance of free testosterone. J Steroid Biochem 1972;3:421-6.
16. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study [published erratum appears in JAMA 1997;278:206]. JAMA 1997;277: 467-71.
17. Huskey SW, Dean DC, Miller RR, Rasmusson GH, Chiu SH. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride [published erratum appears in Drug Metab Dispos 1996;24:695]. Drug Metab Dispos 1995;23: 1126-35.
18. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371-4.
19. Devgan SA, Henderson BE, Yu MC, Shi CY, Pike MC, Ross RK, et al. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate 1997;33:9-12.